EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Dividend confirmation
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that the Board has confirmed a cash dividend of 1p per ordinary share which will be paid on 1 December 2020.
The dividend timetable dates are below:
|
Ex-dividend date: |
5 November 2020 |
|
Record date: |
6 November 2020 |
|
Payment date: |
1 December 2020 |
|
EKF Diagnostics Holdings plc |
||
|
Christopher Mills, Non-executive Chairman |
Tel: +44 (0) 29 2071 0570 |
|
|
Julian Baines, CEO |
|
|
|
Richard Evans, FD & COO |
|
|
|
|
|
|
|
N+1 Singer |
Tel: 020 7496 3000 |
|
|
Aubrey Powell / George Tzimas (Corporate Finance) |
|
|
|
|
|
|
|
Walbrook PR Limited |
Tel: +44 (0) 20 7933 8780 or ekf@walbrookpr.com |
|
|
Paul McManus / Lianne Cawthorne |
Mob: +44 (0) 7980 541 893 / +44 (0) 7584 391 303 |
|
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.